<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Conjugated equine estrogens (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Conjugated equine estrogens (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Conjugated equine estrogens (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11676" href="/d/html/11676.html" rel="external">see "Conjugated equine estrogens (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="15982" href="/d/html/15982.html" rel="external">see "Conjugated equine estrogens (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F8090824"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Endometrial cancer: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.  Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be taken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal genital bleeding. </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular disease: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens 0.625 mg alone, relative to placebo.</p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke, and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Breast cancer:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The WHI estrogen-plus-progestin substudy demonstrated an increased risk of invasive breast cancer.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dementia: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Estrogen-alone therapy should not be used for the prevention of dementia. The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily conjugated estrogens (0.625 mg) alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen plus progestin therapy should not be used for the prevention of dementia. The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk vs benefit:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In the absence of comparable data, these risks should be assumed to be similar for other doses of conjugated estrogens (with or without medroxyprogesterone acetate) and other dosage forms of estrogens (with or without progestins). Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8090832"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Premarin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869142"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>C.E.S. [DSC];</li>
<li>Premarin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8090845"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Estrogen Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F8090925"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fae0ae65-c96c-4591-ade4-935b592626f5">Abnormal uterine bleeding, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding, acute:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> For use in patients without high risk of thrombosis. High dose estrogen therapy typically requires a concurrent antiemetic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31441825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31441825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hemodynamically unstable patients:</i>
<b>Note: </b>Surgical management is preferred; however, IV estrogen may be used in select patients (ie, those in whom delayed therapeutic onset is unlikely to cause adverse outcomes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23635706','lexi-content-ref-Zacur.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23635706','lexi-content-ref-Zacur.1'])">Ref</a></span>). <b>IM, IV:</b> 25 mg every 4 to 6 hours for 24 hours, then transition to oral therapy (eg, a combined oral contraceptive taper) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23635706','lexi-content-ref-31441825','lexi-content-ref-Zacur.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23635706','lexi-content-ref-31441825','lexi-content-ref-Zacur.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hemodynamically stable patients:</i>
<b>Note: </b>Oral estrogen may be used as an alternative to combined oral contraceptives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Zacur.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Zacur.1'])">Ref</a></span>). <b>Oral (off-label route) (alternative agent):</b> 2.5 mg every 6 hours. When bleeding subsides or is minimal, may decrease dose to 2.5 mg twice daily for a total duration of 21 to 25 days. Follow with progestin therapy for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8828563','lexi-content-ref-Zacur.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8828563','lexi-content-ref-Zacur.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8423721-7a23-4fed-bf36-91a0c75f98e6">Breast cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic:</b>
<b>Oral:</b> 10 mg 3 times/day for at least 3 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bdf1e035-dfe9-427e-9d57-84e89b0136ec">Osteoporosis, postmenopausal, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, postmenopausal, prevention (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an alternative to first-line therapies to prevent bone loss in patients with moderate to severe vasomotor symptoms of menopause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32427503','lexi-content-ref-34448749','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32427503','lexi-content-ref-34448749','lexi-content-ref-25182228'])">Ref</a></span>). In patients <b>without</b> menopausal vasomotor symptoms who require fracture risk reduction, other first-line therapies are preferred. Avoid initiating in patients &gt;60 years of age or who are &gt;10 years beyond menopause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34448749','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34448749','lexi-content-ref-25182228'])">Ref</a></span>). Ensure adequate calcium and vitamin D intake during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 0.3 mg/day administered once daily or cyclically (3 weeks on, 1 week off, <b>or</b> 25 days on, 5 days off), depending on medical assessment of patient. Dosage adjustments are individualized based on menopausal symptoms; use the lowest effective dose. Doses ≥0.3 mg/day have been associated with bone mineral density (BMD) benefits; separate therapy to reduce the risk of osteoporotic fractures is not required for patients who attain BMD targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12020302','lexi-content-ref-34448749','lexi-content-ref-Rosen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12020302','lexi-content-ref-34448749','lexi-content-ref-Rosen.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> The optimal duration of therapy has not been established. Estrogens should be used for the shortest duration possible consistent with treatment goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32427503','lexi-content-ref-25182228','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32427503','lexi-content-ref-25182228','lexi-content-ref-Manu.1'])">Ref</a></span>). Extended use may be considered in patients in whom alternative therapies are not appropriate and when benefits of therapy are expected to outweigh risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34448749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34448749'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Discontinuation of therapy:</b> If continued osteoporosis therapy is necessary, switch to antiresorptive therapy (eg, with a bisphosphonate) following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34448749','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34448749','lexi-content-ref-25182228'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13531fc0-f759-4ce8-adf1-0f2fb51f128a">Prostate cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced:</b>
<b>Oral:</b> 1.25 to 2.5 mg 3 times/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33847005-a8a0-48f0-b6fe-f3530ab1256e">Secondary amenorrhea, hypoestrogenism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary amenorrhea, hypoestrogenism (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Manufacturer’s labeling: Oral:</b> 1.25 mg/day given cyclically; adjust according to severity of symptoms and patient response. For maintenance, adjust to the lowest effective dose. In a patient with a uterus, give estrogen with a progestogen (ie, a natural progesterone or synthetic progestin).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54fec27d-11d7-4241-8106-9aca224edbe6">Uremic bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uremic bleeding (off-label use):</b>
<b>IV:</b> 0.6 mg/kg/day for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1963650','lexi-content-ref-3018561','lexi-content-ref-2850395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1963650','lexi-content-ref-3018561','lexi-content-ref-2850395'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause (alternative agent):</b>
<b>Note<i>:</i></b>For use in symptomatic patients who are &lt;60 years of age or within 10 years of menopause who do not have contraindications to hormone therapy (eg, breast cancer) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>). Nonoral estrogen preparations are preferred in patients with hypertriglyceridemia, risk factors for venous thromboembolic disease, active gallbladder disease, and/or migraine headache with aura (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martin.1','lexi-content-ref-20230416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martin.1','lexi-content-ref-20230416'])">Ref</a></span>). Initiate at the lowest dose and increase approximately every 4 weeks as needed to relieve symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martin.1'])">Ref</a></span>). Evaluate routinely to minimize drug exposure and optimize administration route. Younger patients (eg, bilateral oophorectomy) may require higher doses. In patients with a uterus, give estrogen with a progestogen (ie, a natural progesterone or synthetic progestin), dosed either cyclically (preferred in late menopausal transition or early postmenopause) or continuously (preferred if &gt;2 to 3 years postmenopause) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martin.1','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martin.1','lexi-content-ref-35797481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.3 mg per day. Dosage range: 0.3 to 1.25 mg per day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> Not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer and with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, nonoral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3679489c-0513-47c2-abaf-018b39b0ff61">Vulvar and vaginal atrophy associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vulvar and vaginal atrophy associated with menopause:</b>
<b>Oral:</b> Initial: 0.3 mg/day. The lowest dose that will control symptoms should be used. May be given cyclically or daily, depending on medical assessment of patient. Adjust dose based on patient's response.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990498"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987793"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated with hepatic dysfunction or disease.</p></div>
<div class="block doe drugH1Div" id="F8090926"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The Beers Criteria recommends avoiding systemic estrogen therapy in postmenopausal patients ≥65 years of age (independent of diagnosis or condition). In older postmenopausal patients already taking systemic estrogens, consider deprescribing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>). Duration of use is not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, nonoral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812609"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15982" href="/d/html/15982.html" rel="external">see "Conjugated equine estrogens (systemic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7471abe8-bd58-44ac-b865-e47b18736eb5">Constitutional delay of growth and puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constitutional delay of growth and puberty (CDGP) (females): </b>Limited data available: <b>Note:</b> Begin with the lowest available dose and gradually increase. Obtain bone age every 6 months to avoid premature epiphyseal closure. If treatment continues beyond 1 year or breast growth is significant and has plateaued or breakthrough bleeding occurs, add cyclic progesterone. Continue until menstruation has been established, or longer if clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078','lexi-content-ref-Santos.2014','lexi-content-ref-Sperling.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078','lexi-content-ref-Santos.2014','lexi-content-ref-Sperling.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: Initial: 0.3 mg once daily; continue for 6 to 12 months then evaluate serum parameters and adjust accordingly; if a lower dose needed, consider a different estrogen preparation; requirements may change over the course of puberty; duration of therapy variable; once bone age advanced, may consider discontinuation of therapy (patient may continue pubertal advancement on own) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Melmed.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Melmed.2011'])">Ref</a></span>). <b>Note:</b> Use of other estrogens (eg, estradiol) is preferred; if conjugated estrogens deemed necessary, the transdermal route may be preferred due to observed cardiovascular risks in post-menopausal females with the systemic route (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Melmed.2011','lexi-content-ref-22296078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Melmed.2011','lexi-content-ref-22296078'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="198c1fd0-3322-49d2-9491-365a2ef6d5ea">Dysfunctional uterine bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysfunctional uterine bleeding: </b>Limited data available: Adolescents: IV: 25 mg every 4 to 6 hours for 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23635706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23635706'])">Ref</a></span>); if patient hemodynamically unstable, may consider doses every 3 to 4 hours for 3 to 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sperling.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sperling.2014'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="046ca40a-0fc4-4f0f-b6cf-534751481989">Hypogonadism, hypoestrogenism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypogonadism, hypoestrogenism (females):</b> Limited data available: <b>Note:</b> Begin with the lowest available dose and gradually increase dose over 2 to 3 years. Obtain bone age every 6 months to avoid premature epiphyseal closure. As puberty progresses, cyclic progesterone will need added (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078','lexi-content-ref-Santos.2014','lexi-content-ref-Sperling.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078','lexi-content-ref-Santos.2014','lexi-content-ref-Sperling.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: Initial: 0.3 mg once daily, titrate at 6 to 12 months intervals to 0.45 mg once daily and then 0.625 mg once daily. After the first 4 to 6 months of therapy or once breakthrough bleeding occurs, estrogen should be switched from continuous to cyclic therapy and administered for the first 21 days of the month in combination with periodic progesterone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Melmed.2011','lexi-content-ref-22296078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Melmed.2011','lexi-content-ref-22296078'])">Ref</a></span>). Overall estrogen replacement will be of extended duration and in some cases lifelong; experts suggest transitioning to transdermal estradiol therapy when able. Some experts suggest an initial dose of 0.1625 mg once daily and then titrating upwards every 6 to 12 months (0.3, 0.45, 0.625 mg once daily, respectively); however, an appropriate commercially available dosage form is not available in the US (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078'])">Ref</a></span>). <b>Note:</b> Use of other estrogens (eg, estradiol) is preferred; if conjugated estrogens deemed necessary, the transdermal route may be preferred due to observed cardiovascular risks in post-menopausal females with the systemic route (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Melmed.2011','lexi-content-ref-26680580','lexi-content-ref-22296078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Melmed.2011','lexi-content-ref-26680580','lexi-content-ref-22296078'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c5e6cbb8-2619-46d9-9bba-b4c59c48b5ce">Turner syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Turner syndrome</b>: Limited data available: <b>Note:</b> Estradiol is preferable to initiate hormone replacement therapy in females with Turner syndrome (particularly transdermal route); therapy is initiated around 12 years of age, and slowly increased over 2 to 4 years to adult estrogen levels; once achieved may consider transition to conjugated estrogens although transdermal preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17047017','lexi-content-ref-27018757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17047017','lexi-content-ref-27018757'])">Ref</a></span>). Adolescents ≥14 years: Usual dose: 1.25 to 2.5 mg once daily; reported range: 0.625 to 2.5 mg; adjust dose based on response and serum parameters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17047017','lexi-content-ref-27018757','lexi-content-ref-22139404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17047017','lexi-content-ref-27018757','lexi-content-ref-22139404'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729713"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; estrogens may cause water retention, monitor fluid status in patients with renal disorders.</p></div>
<div class="block dohp drugH1Div" id="F52729714"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use is contraindicated with hepatic dysfunction or disease.</p></div>
<div class="block adr drugH1Div" id="F8090868"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Percentages reported in postmenopausal women following oral use.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (26% to 32%), pain (17% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (15% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginal hemorrhage (2% to 14%), mastalgia (7% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (13% to 14%), arthralgia (7% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (10% to 12%), sinusitis (6% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Depression (5% to 8%), dizziness (4% to 6%), nervousness (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (6% to 7%), flatulence (6% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginitis (5% to 7%), leukorrhea (4% to 7%), vulvovaginal candidiasis (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (7% to 8%), leg cramps (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Increased cough (4% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (injection): Local: Injection site phlebitis, pain at injection site, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abnormal uterine bleeding, alopecia, anaphylaxis, angioedema, bloating, breast hypertrophy, breast tenderness, cerebrovascular accident, change in cervical secretions, change in libido, chloasma, cholestatic jaundice, contact lens intolerance, decreased glucose tolerance, deep vein thrombosis, dementia, dysmenorrhea, edema, endometrial carcinoma, endometrial hyperplasia, erythema multiforme, erythema nodosum, exacerbation of asthma, exacerbation of epilepsy, exacerbation of hepatic hemangioma, exacerbation of porphyria, fibrocystic breast changes, galactorrhea, gallbladder disease, growth potentiation of benign meningioma, gynecomastia, hirsutism, hypersensitivity reaction, hypertension, increased serum triglycerides, irritability, ischemic colitis, malignant neoplasm of breast, migraine, mood changes, myocardial infarction, nausea, nipple discharge, ovarian carcinoma, pancreatitis, pelvic pain, pulmonary embolism, retinal thrombosis, skin rash, superficial venous thrombosis, thrombophlebitis, urticaria, uterine fibroids (increased size), vomiting, vulvovaginal candidiasis, weight changes</p></div>
<div class="block coi drugH1Div" id="F8090856"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Angioedema or anaphylactic reaction to estrogens or any component of the formulation; undiagnosed abnormal genital bleeding; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); breast cancer (except in appropriately selected patients being treated for metastatic disease); estrogen-dependent tumor (known or suspected); hepatic impairment or disease; known protein C, protein S, antithrombin deficiency or other known thrombophilic disorders; pregnancy</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Endometrial hyperplasia; partial or complete vision loss due to ophthalmic vascular disease; migraine with or without aura</p></div>
<div class="block war drugH1Div" id="F8090857"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: Anaphylaxis requiring emergency medical management has been reported within minutes to hours of taking conjugated estrogen (CE) tablets. Angioedema involving the face, feet, hands, larynx, and tongue has also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: Based on data from the Women’s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in patients who are postmenopausal using CEs in combination with medroxyprogesterone acetate (MPA). Observational studies noted this risk declines once therapy is discontinued. The WHI study did not observe an increased risk of invasive breast cancer in patients with a hysterectomy using CE alone. The risk of breast cancer in patients who are postmenopausal on hormone therapy may depend upon type of estrogen and/or progestogen, dose, timing of therapy initiation, duration of therapy, route of administration, and individual patient characteristics (AACE/ACE [Cobin 2017]; NAMS 2022). Hormone therapy may be considered for patients who have entered menopause following an oophorectomy if the patient does not have a personal history of breast cancer; treatment for menopausal symptoms should be individualized (SGO/ASRM [Chen 2019]). Hormone therapy may be associated with increased breast density (NAMS 2022); an increase in abnormal mammogram findings requiring further evaluation has been reported with estrogen alone or in combination with progestogen therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dementia: Do not use estrogens with or without progestin to prevent dementia. In the Women’s Health Initiative Memory Study, an increased incidence of probable dementia was observed in patients ≥65 years of age taking CE alone or in combination with MPA. Because the WHI memory studies were conducted in patients ≥65 years of age, it is unknown if these findings apply to younger patients who are postmenopausal; however, hormone therapy is not recommended at any age to prevent or treat cognitive decline or dementia (AACE [Goodman 2011]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometrial cancer: The use of unopposed estrogen in patients with a uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Perform adequate diagnostic measures, including endometrial sampling if indicated, to rule out malignancy in postmenopausal patients with undiagnosed abnormal vaginal bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. The risk of endometrial cancer appears to be dose and duration dependent, greatest with use ≥5 years, and may persist following discontinuation of therapy (NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometriosis: Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestogen in patients with residual endometriosis posthysterectomy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased high-density lipoprotein cholesterol and decreased low-density lipoprotein cholesterol. Triglycerides may also be increased in patients with preexisting hypertriglyceridemia; discontinue if pancreatitis occurs. Use with caution in patients with familial defects of lipoprotein metabolism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cancer: Available information related to the use of menopausal estrogen or estrogen/progestogen therapy and risk of ovarian cancer is inconsistent. If an association is present, the absolute risk is likely rare and may be influenced by duration of therapy (AACE [Goodman 2011]; ES [Stuenkel 2015]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue use if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use caution in patients with asthma; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: May impair glucose tolerance; use caution in patients with diabetes. Prior to therapy, consider age, cardiovascular and metabolic risk factors in patients previously diagnosed with diabetes (AACE/ACE [Cobin 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Do not use estrogens with or without progestin to prevent cardiovascular disease. The WHI studies reported an increased risk of deep vein thrombosis (DVT) and stroke with CE and an increased risk of DVT, stroke, pulmonary emboli, and myocardial infarction using CE with MPA in postmenopausal patients 50 to 79 years of age. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, systemic lupus erythematosus (SLE), obesity, tobacco use, and/or history of venous thromboembolism. Manage risk factors appropriately; discontinue use immediately if adverse cardiovascular events occur or are suspected. Due to possible lower risk of thrombotic events, transdermal administration may be preferred for treating vasomotor symptoms of menopause in patients with risk factors for cardiovascular disease (AACE/ACE [Cobin 2017]; ACOG 2013b; ES [Stuenkel 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diseases exacerbated by fluid retention: Use with caution in patients with diseases that may be exacerbated by fluid retention, including cardiac or renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epilepsy: Use caution with epilepsy; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic dysfunction: Estrogens may be poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in patients with hereditary angioedema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoparathyroidism: Use caution in patients with hypoparathyroidism; estrogen-induced hypocalcemia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use caution with migraine; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use with caution in patients with porphyria; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematosus: Use with caution in patients with SLE; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Prior to puberty, estrogens may cause premature closure of the epiphyses. Premature breast development, vaginal bleeding and vaginal cornification may be induced in girls. Modification of the normal puberty process may occur in boys.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Whenever possible, discontinue estrogens at least 4 to 6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Although the injection is indicated for short-term use only, consider all warnings and precautions associated with oral administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of use: Not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, nonoral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Genitourinary syndrome of menopause: Low dose vaginal estrogen is preferred over systemic therapy for genitourinary syndrome of menopause in the absence of vasomotor symptoms due to increased efficacy and decreased systemic effects (eg, cardiovascular effects, cancer risk) (NAMS 2022; NAMS 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis use: In patients with premature menopause, hormone therapy to prevent bone loss may be used unless otherwise contraindicated; reassess therapy when the average age of menopause is reached. It is also an appropriate bone-active therapy for patients with vasomotor symptoms who are &lt;60 years of age or within 10 years of menopause onset. Use may be considered for patients at high risk of fractures who are not candidates for other osteoporosis therapies (ES [Eastell 2019]; NAMS 2022; NAMS 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Risks vs benefits: When used for the relief of menopausal symptoms or increased risk of bone fracture/loss, the benefit-risk of hormone therapy is most favorable if started in patients who have no contraindications to therapy, are &lt;60 years of age, within 10 years of menopause onset, have a favorable lipid profile, and do not have the factor V Leiden genotype or metabolic syndrome. Consider cardiovascular disease risk factors when evaluating therapy and route of administration (AACE/ACE [Cobin 2017]; NAMS 2022). Use for the shortest duration possible at the lowest effective dose consistent with treatment goals and risks for the individual patient. Reevaluate patients as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from WHI studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal patients. Other combinations and dosage forms of estrogens and progestins were not studied. Assume outcomes reported from clinical trials using CE with or without MPA to be similar for other doses and other dosage forms of estrogens and progestins until comparable data become available.</p></div>
<div class="block foc drugH1Div" id="F8090954"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premarin: 25 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premarin: 0.3 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premarin: 0.45 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premarin: 0.625 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premarin: 0.9 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premarin: 1.25 mg [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p></div>
<div class="block geq drugH1Div" id="F8090843"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F8090956"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Premarin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $441.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Premarin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg (per each): $8.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.45 mg (per each): $8.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.625 mg (per each): $8.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.9 mg (per each): $8.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25 mg (per each): $8.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869143"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premarin: 25 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">C.E.S.: 0.625 mg [DSC] [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye), methylparaben, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premarin: 0.3 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premarin: 0.625 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premarin: 1.25 mg [contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p></div>
<div class="block adm drugH1Div" id="F8090936"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection:</b> May be administered IV or IM; when administered IV, administer slowly to avoid the occurrence of a flushing reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral tablet:</b> Administer at the same time each day. May be administered without regard to meals. If a dose is missed, administer as soon as possible unless it is almost time for the next dose, then skip the missed dose and go back to the normal schedule. Do not administer 2 doses at the same time.</p>
<p style="text-indent:-2em;margin-left:4em;">Vasomotor symptoms associated with menopause: Recently menopausal patients (&lt;2 years) with a uterus may benefit from a cyclic regimen (continuous regimens may be associated with unscheduled bleeding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26444994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26444994'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614343"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals; administration of dose at bedtime may decrease adverse effects</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: May be administered IV or IM; administer slow IV to avoid vascular flushing</p></div>
<div class="block hazard drugH1Div" id="F49132517"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends single gloving for administration of intact tablets or capsules. For injectable products, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F8090850"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding, acute:</b> Treatment of acute abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: For short term use only to provide a rapid and temporary increase in estrogen levels in patients with acute abnormal uterine bleeding (ie, heavy menstrual bleeding) without contraindications to estrogen and no known or suspected bleeding disorders (ACOG 2013a; ACOG 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic:</b> Treatment of metastatic breast cancer (palliation only) in appropriately selected males and postmenopausal females.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, postmenopausal, prevention:</b> Prevention of postmenopausal osteoporosis.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: For use only in patients who are postmenopausal at significant risk of osteoporosis; consider use of nonestrogen medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced:</b> Treatment of androgen-dependent prostatic cancer (palliation).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary amenorrhea, hypoestrogenism:</b> Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause:</b> Treatment of moderate to severe vasomotor symptoms associated with menopause.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vulvar and vaginal atrophy associated with menopause:</b> Treatment of moderate to severe vulvar and vaginal atrophy due to menopause.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: When used solely for the treatment of vulvar and vaginal atrophy, consider topical vaginal products.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The International Society for the Study of Women’s Sexual Health and The North American Menopause Society have endorsed the term genitourinary syndrome of menopause (GSM) as new terminology for vulvovaginal atrophy. The term GSM encompasses all genital and urinary signs and symptoms associated with a loss of estrogen due to menopause (Portman 2014).</p></div>
<div class="block off-label drugH1Div" id="F25725535"><span class="drugH1">Use: Off-Label: Adult</span><p>Uremic bleeding</p></div>
<div class="block mst drugH1Div" id="F8090826"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Premarin may be confused with Primaxin, Provera, Remeron</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappropriate medications to be avoided in postmenopausal patients ≥65 years of age (independent of diagnosis or condition) due to their carcinogenic potential (breast and endometrium) and lack of cardioprotection or cognitive protection. Starting therapy in postmenopausal patients ≥60 years of age has greater risks (eg, heart disease, stroke, blood clots, dementia) than benefits. In postmenopausal patients already taking systemic estrogens, consider deprescribing (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8090878"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>
<div class="block dri drugH1Div" id="F8090879"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Estrogen Derivatives may enhance the adverse/toxic effect of Chlorprothixene. Estrogen Derivatives may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Estrogen Derivatives may diminish the diagnostic effect of Cosyntropin.  Management: Discontinue estrogen containing drugs 4 to 6 weeks prior to cosyntropin (ACTH) testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Estrogen Derivatives may diminish the therapeutic effect of Growth Hormone Analogs.  Management: Initiate somapacitan at 2 mg once weekly in patients receiving oral estrogens. Monitor for reduced efficacy of growth hormone analogs; increased doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): Estrogen Derivatives may increase the serum concentration of Hydrocortisone (Systemic). Estrogen Derivatives may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Estrogen Derivatives may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: Estrogen Derivatives may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Estrogen Derivatives may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking estrogen derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Estrogen Derivatives. Protease Inhibitors may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: Estrogen Derivatives may enhance the adverse/toxic effect of Raloxifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Estrogen Derivatives may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Estrogen Derivatives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F8090883"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Folic acid absorption may be decreased.</p></div>
<div class="block pri drugH1Div" id="F8090852"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">In general, the use of estrogen and progestogen as in combination hormonal contraceptives have not been associated with teratogenic effects when inadvertently taken early in pregnancy.</p></div>
<div class="block brc drugH1Div" id="F8090855"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Estrogens can be detected in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen has been shown to decrease the quantity and quality of human milk. The manufacturer recommends that caution be used if administered to a breastfeeding patient.</p></div>
<div class="block dic drugH1Div" id="F8090928"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis. Powder for reconstitution for injection (25 mg) contains lactose 200 mg.</p></div>
<div class="block mop drugH1Div" id="F8090941"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to therapy, baseline risk for breast cancer and CVD. During therapy, age-appropriate breast and pelvic exams; blood pressure; unscheduled bleeding lasting &gt;6 months for endometrial pathology (sooner in patients with obesity, diabetes, or a history of endometrial cancer); serum triglycerides (2 weeks after starting therapy in patients with baseline level &gt;200 mg/dL); TSH (6 to 12 weeks after starting oral therapy in patients taking thyroid replacement) (ES [Stuenkel 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">Menopausal symptoms: Efficacy beginning 1 to 3 months after starting therapy, then every 6 to 12 months as appropriate. Evaluate duration of treatment at least annually (ES [Stuenkel 2015]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Monitoring of FSH and serum estradiol is not useful when managing vasomotor symptoms or genitourinary symptoms of menopause.</p>
<p style="text-indent:-2em;margin-left:4em;">Abnormal uterine bleeding, acute: Response to treatment that may be dependent upon etiology of bleed (ACOG 2013a; Haamid 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of osteoporosis: Bone density measurement</p>
<p style="text-indent:-2em;margin-left:4em;">Uremic bleeding: Bleeding time</p></div>
<div class="block pha drugH1Div" id="F8090900"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Conjugated estrogens contain a mixture of estrone sulfate, equilin sulfate, 17 alpha-dihydroequilin, 17 alpha-estradiol and 17 beta-dihydroequilin. Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in patients who are postmenopausal.</p></div>
<div class="block phk drugH1Div" id="F8090903"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely distributes throughout the body; sex hormone target organs contain higher concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Binds to sex-hormone-binding globulin and albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4; estradiol is converted to estrone and estriol; estrone is also converted to estriol and is converted to estradiol (<b>Note: </b>A dynamic equilibrium of metabolic interconversions between estrogens exists in the circulation); also undergoes enterohepatic recirculation (avoided with vaginal administration); estrone sulfate is the main metabolite in patients who are postmenopausal.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Total estrone: 27 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Total estrone: 7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily estriol, also as estradiol, estrone, and conjugates.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961972"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dagynil | Premarin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Belestar | Livomarin | Premarin | Premarin CD</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Equigyne | Premarin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Estrinolon | Estrogenon | Estroplus | Menoprin | Menosedan | Prem | Premarin | Repogen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Premarin | Transannon</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Climatrol e | Conpremin | Estrarona | Estrogenos conjugados | Feveny | Profemina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ayerogen | Estermax | Estrogenos conjugados | Feveny | Premarin | Suplestrol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Climopax mono | Presomen</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ayerogen | Climatrol e | Estrarona | Estrogefran | Perimex | Premarin | Terapova</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ayerogen | Esterhoy | Estrarona | Premarin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Equin | Premarin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Equin | Premarin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Premarin | Presomen</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Esthero | Premarin | Premarose</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Premaril | Premarin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Conjugase | Espauz | Estrin | Premarin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Hyhorin | Premarin | Premarin asahikasei | Romeda | Sefac</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dagynil | Esmarin | Premarin | Premina | Srogen</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Hormoplex | Premarin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Climopax mono | Hormoplex | Premarin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">C.e.s. | Elrredin | Estrogenos conjugados | Fahifem | Neradin | Premarin | Premone | Renestra | Shrogen | Sixdin | Terapova</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Conjugase | Premarin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Conjya</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dagynil | Premarin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ayerogen | Climatrol e | Estrarona | Feveny | Premarin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Premarin | Primax</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Co estrogen | Dyestro | Menorin | Premarin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Premarin | Presomen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cenestin | Estrogenos conjugatos | Premarin | Premarin low dose</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Estrarona | Ginestrogenos</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Hormoplex | Premarin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Estromon fc | Premarin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Azumon | Conest | Conjuestrogen | Conjugated estroge | Dagynil | Equigyne | Equitor | Estrolan | Estromon | Eyzu | Lovegen | Premarin | Romeda | Yipo</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Hormoplex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Estrarona | Premarin | Premarin CD</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Climatrol e | Menostat | Premarin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Premarin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Estrin | Premarin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.2017">
<a name="USP.2017"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635706">
<a name="23635706"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. <i>Obstet Gynecol</i>. 2013a;121(4):891-896. doi: 10.1097/01.AOG.0000428646.67925.9a.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/23635706/pubmed" id="23635706" target="_blank">23635706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635705">
<a name="23635705"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. <i>Obstet Gynecol</i>. 2013b;121(4):887-890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/23635705/pubmed" id="23635705" target="_blank">23635705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31441825">
<a name="31441825"></a>American College of Obstetricians and Gynecologists (ACOG). Screening and management of bleeding disorders in adolescents with heavy menstrual bleeding: committee opinion no. 785. <i>Obstet Gynecol</i>. 2019;134(3):e71-e83. doi:10.1097/AOG.0000000000003411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/31441825/pubmed" id="31441825" target="_blank">31441825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22401913">
<a name="22401913"></a>Anderson GL, Chlebowski RT, Aragaki AK, et al, "Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial," <i>Lancet Oncol,</i> 2012,13(5):476-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/22401913/pubmed" id="22401913" target="_blank">22401913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15082697">
<a name="15082697"></a>Anderson GL, Limacher M, Assaf AR, et al, "Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial." <i>JAMA</i>, 2004, 291(14):1701-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/15082697/pubmed" id="15082697" target="_blank">15082697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17047017">
<a name="17047017"></a>Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. <i>J Clin Endocrinol Metab</i>. 2007;92(1):10-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/17047017/pubmed" id="17047017" target="_blank">17047017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):1-46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31606136">
<a name="31606136"></a>Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T. Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine evidence-based review. <i>Fertil Steril</i>. 2019;112(6):1034-1042. doi:10.1016/j.fertnstert.2019.07.1349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/31606136/pubmed" id="31606136" target="_blank">31606136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19196674">
<a name="19196674"></a>Chlebowski RT, Kuller LH, Prentice RL, et al, "Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women," <i>N Engl J Med</i>, 2009, 360(6):573-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/19196674/pubmed" id="19196674" target="_blank">19196674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8828563">
<a name="8828563"></a>Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. <i>Am J Obstet Gynecol</i>. 1996;175(3, pt 2):787-792. doi:10.1016/s0002-9378(96)80086-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/8828563/pubmed" id="8828563" target="_blank">8828563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703650">
<a name="28703650"></a>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause-2017 update. <i>Endocr Pract</i>. 2017;23(7):869-880. doi: 10.4158/EP171828.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/28703650/pubmed" id="28703650" target="_blank">28703650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20581664">
<a name="20581664"></a>DeSancho MT, Dorff T, and Rand JH, "Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy," <i>Blood Coagul Fibrinolysis</i>, 2010, 21(6):534-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/20581664/pubmed" id="20581664" target="_blank">20581664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6281704">
<a name="6281704"></a>DeVore GR, Owens O, and Kase N, "Use of Intravenous Premarin in the Treatment of Dysfunctional Uterine Bleeding -- A Double-Blind Randomized Control Study," <i>Obstet Gynecol</i>, 1982, 59(3):285-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/6281704/pubmed" id="6281704" target="_blank">6281704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.2017">
<a name="Eichenwald.2017"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27018757">
<a name="27018757"></a>Gawlik A, Hankus M, Such K, et al. Hypogonadism and sex steroid replacement therapy in girls with turner syndrome. <i>J Pediatr Adolesc Gynecol</i>. 2016;29(6):542-550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/27018757/pubmed" id="27018757" target="_blank">27018757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193047">
<a name="22193047"></a>Goodman NF, Cobin RH, Ginzburg SB, et al; American Association of Clinical Endocrinologists (AACE). American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. <i>Endocr Pract</i>. 2011;17(suppl 6):1-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/22193047/pubmed" id="22193047" target="_blank">22193047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28108214">
<a name="28108214"></a>Haamid F, Sass AE, Dietrich JE. Heavy menstrual bleeding in adolescents. <i>J Pediatr Adolesc Gynecol.</i> 2017;30(3):335-340. doi: 10.1016/j.jpag.2017.01.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/28108214/pubmed" id="28108214" target="_blank">28108214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17322926">
<a name="17322926"></a>Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. <i>Nat Clin Pract Nephrol</i>. 2007;3(3):138-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/17322926/pubmed" id="17322926" target="_blank">17322926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1963650">
<a name="1963650"></a>Heistinger M, Stockenhuber F, Schneider B, et al. Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. <i>Kidney Int</i>. 1990;38(6):1181-1186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/1963650/pubmed" id="1963650" target="_blank">1963650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16476878">
<a name="16476878"></a>Hsia J, Langer RD, Manson JE, et al, "Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative," <i>Arch Intern Med</i>, 2006, 166(3):357-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/16476878/pubmed" id="16476878" target="_blank">16476878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9718051">
<a name="9718051"></a>Hulley S, Grady D, Bush T, et al, “Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group,” <i>JAMA</i>, 1998, 280(7):605-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/9718051/pubmed" id="9718051" target="_blank">9718051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16995570">
<a name="16995570"></a>Janfaza M, Sherman TI, Larmore KA, Brown-Dawson J, Klein KO. Estradiol levels and secretory dynamics in normal girls and boys as determined by an ultrasensitive bioassay: a 10 year experience. <i>J Pediatr Endocrinol Metab</i>. 2006;19(7):901-909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/16995570/pubmed" id="16995570" target="_blank">16995570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22139404">
<a name="22139404"></a>Kodama M, Komura H, Kodama T, Nishio Y, Kimura T. Estrogen therapy initiated at an early age increases bone mineral density in Turner syndrome patients. <i>Endocr J</i>. 2012;59(2):153-159.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/22139404/pubmed" id="22139404" target="_blank">22139404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12020302">
<a name="12020302"></a>Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. <i>JAMA</i>. 2002;287(20):2668-2676. doi:10.1001/jama.287.20.2668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/12020302/pubmed" id="12020302" target="_blank">12020302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3018561">
<a name="3018561"></a>Livio M, Mannucci PM, Vigano G, et al, “Conjugated Estrogens for the Management of Bleeding Associated With Renal Failure,” <i>N Engl J Med</i>, 1986, 315(12):731-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/3018561/pubmed" id="3018561" target="_blank">3018561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Martin.1">
<a name="Martin.1"></a>Martin KA, Barbieri RL. Treatment of menopausal symptoms with hormone therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8123965">
<a name="8123965"></a>McCarthy ML and Stoukides CA, “Estrogen Therapy of Uremic Bleeding,” <i>Ann Pharmacother</i>, 1994, 28(1):60-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/8123965/pubmed" id="8123965" target="_blank">8123965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Melmed.2011">
<a name="Melmed.2011"></a>Melmed S, Pololnsky KS, Larsen PR, Kronenberg HM, eds. <i>Williams Textbook of Endocrinology</i>. 12th edition. Philadelphia, PA: Elsevier Saunders; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10693183">
<a name="10693183"></a>Minjarez DA and Bradshaw KD, “Abnormal Uterine Bleeding in Adolescents,” <i>Obstet Gynecol Clin North Am</i>, 2000, 27(1):63-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/10693183/pubmed" id="10693183" target="_blank">10693183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10928192">
<a name="10928192"></a>Mitan LA and Slap GB, “Adolescent Menstrual Disorders. Update,” <i>Med Clin North Am</i>, 2000, 84(4):851-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/10928192/pubmed" id="10928192" target="_blank">10928192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19602689">
<a name="19602689"></a>Mørch LS, Løkkegaard E, Andreasen AH, et al, “Hormone Therapy and Ovarian Cancer,” <i>JAMA</i>, 2009, 302(3):298-305.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/19602689/pubmed" id="19602689" target="_blank">19602689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neistein.1991">
<a name="Neistein.1991"></a>Neistein LS, <i>Adolescent Health Care - A Practical Guide</i>, 2nd ed, Baltimore: Urban &amp; Schwarzenberg, 1991, 661-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/Neistein.1991/pubmed" id="Neistein.1991" target="_blank">Neistein.1991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26680580">
<a name="26680580"></a>Norjavaara E, Ankarberg-Lindgren C, Kriström B. Sex steroid replacement therapy in female hypogonadism from childhood to young adulthood. <i>Endocr Dev</i>. 2016;29:198-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/26680580/pubmed" id="26680580" target="_blank">26680580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society (NAMS). Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32852449">
<a name="32852449"></a>North American Menopause Society (NAMS). The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. <i>Menopause</i>. 2020;27(9):976-992. doi:10.1097/GME.0000000000001609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/32852449/pubmed" id="32852449" target="_blank">32852449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35797481">
<a name="35797481"></a>North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. <i>Menopause</i>. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/35797481/pubmed" id="35797481" target="_blank">35797481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22296078">
<a name="22296078"></a>Palmert MR, Dunkel L. Clinical practice. Delayed puberty. <i>N Engl J Med</i>. 2012;366(5):443-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/22296078/pubmed" id="22296078" target="_blank">22296078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25160739">
<a name="25160739"></a>Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. <i>Menopause</i>. 2014;21(10):1063-1068.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/25160739/pubmed" id="25160739" target="_blank">25160739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Premarin.1">
<a name="Premarin.1"></a>Premarin Intravenous (conjugated estrogens) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Premarin.2">
<a name="Premarin.2"></a>Premarin Intravenous (conjugated estrogens) [product monograph]. Kirkland, Quebec, Canada: Wyeth Canada Pfizer Canada Inc, Licensee; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Premarin.3">
<a name="Premarin.3"></a>Premarin tablets (conjugated estrogens) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Premarin.4">
<a name="Premarin.4"></a>Premarin tablets [product information]. Kirkland, Quebec, Canada: Wyeth Canada; December 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20230416">
<a name="20230416"></a>Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. <i>J Thromb Haemost</i>. 2010;8(5):979-986. doi:10.1111/j.1538-7836.2010.03839.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/20230416/pubmed" id="20230416" target="_blank">20230416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.1">
<a name="Rosen.1"></a>Rosen HN, Drezner MK. Menopausal hormone therapy in the prevention and treatment of osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 19, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117397">
<a name="12117397"></a>Rossouw JE, Anderson GL, Prentice RL, et al, “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,”<i>JAMA</i>, 2002, 288(3):321-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/12117397/pubmed" id="12117397" target="_blank">12117397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Santos.2014">
<a name="Santos.2014"></a>Santos XM. <i>Constitutional Delay of Puberty</i>. In Dietrich JE, ed. <i>Female Puberty: A Comprehensive Guide for Clinicians</i>. New York: Springer Science+Business Media; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21156341">
<a name="21156341"></a>Schenck-Gustafsson K, Brincat M, Erel CT, et al; EMAS. EMAS position statement: Managing the menopause in the context of coronary heart disease. <i>Maturitas</i>. 2011;68(1):94-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/21156341/pubmed" id="21156341" target="_blank">21156341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771112">
<a name="12771112"></a>Shumaker SA, Legault C, Rapp SR, et al, “Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,” <i>JAMA</i>, 2003, 289(20):2651-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/12771112/pubmed" id="12771112" target="_blank">12771112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sperling.2014">
<a name="Sperling.2014"></a>Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Philadelphia, PA: Elsevier Saunders; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline [published online ahead of print October 7, 2015]. <i>J Clin Endocrinol Metab</i>. 2015:jc20152236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7807658">
<a name="7807658"></a>The Writing Group for the PEPI Trial, “Effects of Estrogen or Estrogen/Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women,” <i>JAMA</i>, 1995, 273(3):199-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/7807658/pubmed" id="7807658" target="_blank">7807658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21489728">
<a name="21489728"></a>Tremollieres F, Brincat M, Erel CT, et al; European Menopause and Andropause Society. EMAS position statement: Managing menopausal women with a personal or family history of VTE. <i>Maturitas</i>. 2011;69(2):195-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/21489728/pubmed" id="21489728" target="_blank">21489728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2016">
<a name="HHS.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21659542">
<a name="21659542"></a>van Vlijmen EF, Veeger NJ, Middeldorp S, et al, "Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception," <i>Blood</i>, 2011, 118(8):2055-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/21659542/pubmed" id="21659542" target="_blank">21659542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2850395">
<a name="2850395"></a>Viganò G, Gaspari F, Locatelli M, Pusineri F, Bonati M, Remuzzi G. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. <i>Kidney Int</i>. 1988;34(6):853-858.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/2850395/pubmed" id="2850395" target="_blank">2850395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771114">
<a name="12771114"></a>Wassertheil-Smoller S, Hendrix S, Limacher M, et al, “Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women's Health Initiative: A Randomized Trial,” <i>JAMA</i>, 2003, 289:2673-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/conjugated-equine-estrogens-systemic-drug-information/abstract-text/12771114/pubmed" id="12771114" target="_blank">12771114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zacur.1">
<a name="Zacur.1"></a>Zacur HA. Managing an episode of acute uterine bleeding. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed October 20, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9123 Version 334.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
